A Phase 1, Single Ascending Dose, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Xisomab 3G3 in Healthy Adult Subjects

Trial Profile

A Phase 1, Single Ascending Dose, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Xisomab 3G3 in Healthy Adult Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Feb 2018

At a glance

  • Drugs Xisomab 3G3 (Primary)
  • Indications Thrombosis
  • Focus Adverse reactions
  • Sponsors Aronora
  • Most Recent Events

    • 20 Feb 2018 Status changed from active, no longer recruiting to completed.
    • 08 Jan 2018 Planned End Date changed from 1 Apr 2018 to 1 Jun 2018.
    • 08 Jan 2018 Planned primary completion date changed from 1 Nov 2017 to 1 Jan 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top